Trials / Unknown
UnknownNCT00966121
Endoscopic Band Ligation (EBL) Versus Endoscopic Band Ligation and Propranolol for the Prevention of Variceal Rebleeding
RCT Comparing the Efficacies of Endoscopic Variceal Ligation (EBL) and Combined Treatment of Beta-blocker and EBL for the Prevention of Esophageal Variceal Rebleeding
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Korea University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Both propranolol and endoscopic band ligation (EBL) are effective for prevention of variceal rebleeding. Recently several studies compared the efficacy of EBL alone and with a combination of propranolol and EBL. However, the results of recent studies showed discrepancy. This study is performed to compare the efficacy and safety of EBL alone and EBL combined with propranolol in patients without previous history of endoscopic variceal treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | endoscopic band ligation | * Perform EBL within 7 days after randomization * Apply 1-2 band/column/session to varices in the distal 5-7cm of the esophagus till they are eradicated (Disappearance or too small to apply band) with interval of 4weeks (at 4,8,12 weeks after initial treatment). * Acid suppression using proton pump inhibitor until eradicated. * After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months). |
| PROCEDURE | EBL+Propranolol | * Start with 20 mg b.i.d * Adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min * After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months) |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2019-07-01
- Completion
- 2021-07-01
- First posted
- 2009-08-26
- Last updated
- 2017-08-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00966121. Inclusion in this directory is not an endorsement.